



دائرة الصحة  
DEPARTMENT OF HEALTH

# Haematopoietic Stem Cell Transplant (HSCT) Jawda Guidance

Version 5

## Table of Contents

<b>Executive Summary</b> .....	3
<b>About this Guidance</b> .....	4
<b>Submission Timeline: 2025/2026</b> .....	5
<b>Percentage of adult patients with successful engraftment</b> .....	6
<b>Percentage of pediatric patients with successful engraftment</b> .....	7
<b>Percentage of adult patients dying within 100 days of autologous transplant</b> .....	8
<b>Percentage of pediatric patients dying within 100 days of autologous transplant</b> .....	9
<b>Percentage of adult patients alive at 1 year post autologous transplant</b> .....	10
<b>Percentage of pediatric patients alive at 1 year post autologous transplant</b> .....	11
<b>Percentage of adult patients dying within 100 days of allogeneic transplant</b> .....	12
<b>Percentage of pediatric patients dying within 100 days of allogeneic transplant</b> .....	13
<b>Percentage of adult patients alive at 1 year post allogeneic transplant</b> .....	14
<b>Percentage of pediatric patients alive at 1 year post allogeneic transplant</b> .....	15
<b>Percentage of adult patients with successful platelet engraftment</b> .....	16
<b>Percentage of pediatric patients with successful platelet engraftment</b> .....	17
<b>Percentage of Multiple Myeloma Patients Whose Transplant Eligibility Determination Report is Sent to the Referring Hematologist Within 5 Working Days</b> .....	18
<b>Summary of Changes V3 2024</b> .....	19
<b>Summary of Changes V4 2025</b> .....	19
<b>Summary of Changes V5 2026</b> .....	19

### Executive Summary

The Department of Health– Abu Dhabi (DOH) is the regulatory body of the healthcare sector in the Emirate of Abu Dhabi and ensures excellence in healthcare for the community by monitoring the health status of its population.

The Emirate of Abu Dhabi is experiencing a substantial growth in the number of hospitals, centers and clinics. This ranges from school clinics and mobile units to internationally renowned specialist and tertiary academic centers. Although access and quality of care has improved dramatically over the last couple of decades, mirroring the economic upturn and population boom of Emirate of Abu Dhabi, however challenges remain in addressing further improvements.

The main challenges that are presented with increasingly dynamic population include an aging population with increased expectation for treatment, utilization of technology and diverse workforce leading to increased complexity of healthcare provision in Abu Dhabi. All of this results in an increased and inherent risk to quality of care and patient safety.

DOH has developed a dynamic and comprehensive quality framework in order to bring about improvements across the health sector. This guidance pertains to the quality indicators that the Department of Health (DOH) is requiring for quarterly reporting by healthcare facilities operating Haematopoietic Stem Cell Transplantation services in the Emirate of Abu Dhabi.

The guidance sets out the full definition and method of calculation for patient safety and clinical effectiveness indicators. For enquiries about this guidance, please contact [jawda@DoH.gov.ae](mailto:jawda@DoH.gov.ae)

This document is subject for review and therefore it is advisable to always utilize online versions available on the DOH website.

Issued: Version 1, January 2020  
Published Update: Version 2, March 2023  
Version 3, April 2024,  
Version 4, December 2025  
Version 5, June 2026

Effective: Version 5, Q3 2026

### **About this Guidance**

The guidance sets out the definitions and reporting frequency of JAWDA Haematopoietic Stem Cell Transplantation (HSCT) Facilities performance indicators. The Department of Health (DOH), with consultation from local and international expertise of Haematopoietic Stem Cell Transplantation (HSCT), has developed Haematopoietic Stem Cell Transplantation Performance Indicators that are aimed for assessing the degree to which a provider competently and safely delivers the appropriate clinical services to the patient within the optimal period of time.

The Jawda KPI for Haematopoietic Stem Cell Transplantation patients in this guidance include measures to monitor morbidity and mortality in patients undergoing Haematopoietic Stem Cell Transplantation. Healthcare providers are the most qualified professionals to develop and evaluate quality of care for HSCT patients; therefore, it is crucial that clinicians retain a leadership position in defining performance among Haematopoietic Stem Cell Transplantation s healthcare providers.

### **Who is this guidance for?**

All DOH licensed healthcare facilities providing Haematopoietic Stem Cell Transplantation services in the Emirate of Abu Dhabi.

### **How do I follow this guidance?**

Each provider will nominate one member of staff to coordinate, collect, monitor and report Haematopoietic Stem Cell Transplantation services quality indicators data as per communicated dates. The nominated healthcare facility lead must in the first instance e-mail their contact details (if different from previous submission) to [JAWDA@doh.gov.ae](mailto:JAWDA@doh.gov.ae) and submit the required quarterly quality performance indicators through Jawda online portal.

### **What are the Regulations related to this guidance?**

- Legislation establishing the Health Sector
- As per DOH [Policy for Quality and Patient Safety](#) issued January 15<sup>th</sup> 2017, this guidance applies to all DOH Licensed Hospital Healthcare Facilities in the Emirate of Abu Dhabi in accordance with the requirements set out in this Standard.
- DOH Standard on Stem Cell Therapies and Products & Regenerative Medicine

## Submission Timeline: 2025/2026

KPI	DENOMINATOR TIMEFRAME			
	Q1	Q2	Q3	Q4
<b>HSCT001</b> <b>HSCT002</b> <b>HSCT011</b> <b>HSCT012</b>	December 2024 to May 2025	March 2025 to August 2025	June 2025 to November 2025	September 2025 to February 2026
<b>HSCT003</b> <b>HSCT004</b> <b>HSCT007</b> <b>HSCT008</b>	22-Mar-2024 to 21-Mar-2025	22-Jun-2024 to 21-Jun-2025	22-Sep-2024 to 21-Sep-2025	22-Dec-2024 to 21-Dec-2025
<b>HSCT005</b> <b>HSCT006</b> <b>HSCT009</b> <b>HSCT0010</b>	July 2023 to June 2024	October 2023 to September 2024	January 2024 to December 2024	April 2024 to March 2025

## Jawda HSCT Quality Performance Indicators

Type: Haematopoietic Stem Cell Transplantation

Number: HSCT001

<b>KPI Description (title):</b>	<b>Percentage of adult patients with successful engraftment</b>
<b>Domain</b>	Effectiveness
<b>Indicator Type</b>	Outcome
<b>Definition</b>	Percentage of adult patients with successful engraftment
<b>Calculation</b>	<p><b><u>Numerator:</u></b> Number of adult patients (18 years and older) where engraftment was successful (successful defined as neutrophil count of <math>(&gt; 0.5 * 10^9/L)</math> for three consecutive days by day plus 28)</p> <p><b>CPT CODE: 85048</b></p> <p><b><u>Denominator:</u></b> Total number of adult patients (18 years and older) transplanted in the first 6 months of the previous 7-month reporting period</p> <p><b>CPT CODES: 38240, 38241, 38242</b></p> <p><b><u>Denominator Exclusion:</u></b></p> <ul style="list-style-type: none"> <li>• Transplants sourced from umbilical cord blood</li> </ul>
<b>Reporting Frequency</b>	Quarterly
<b>Unit Measure</b>	Percentage
<b>International comparison if available</b>	<ul style="list-style-type: none"> <li>• NHS England. <i>Specialised services quality dashboards metrics metadata (2025–2026)</i>. Published June 30, 2023. Updated May 8, 2026.</li> <li>• NHS England. <i>Specialised services quality dashboards</i>.</li> </ul>
<b>Desired Direction</b>	Higher is better
<b>Data Source</b>	Electronic Medical Record (EMR)

**Jawda HSCT Quality Performance Indicators**

---

Type: Haematopoietic Stem Cell Transplantation

Number: HSCT002

<b>KPI Description (title):</b>	<b>Percentage of pediatric patients with successful engraftment</b>
<b>Domain</b>	Effectiveness
<b>Indicator Type</b>	Outcome
<b>Definition</b>	Percentage of pediatric patients with successful engraftment
<b>Calculation</b>	<p><b><u>Numerator:</u></b> Number of pediatric patients (below 18 years) where engraftment was successful (successful defined as neutrophil count of <math>(&gt; 0.5 * 10^9/L)</math> for three consecutive days by day plus 28)</p> <p><b>CPT CODE: 85048</b></p> <p><b><u>Denominator:</u></b> Total number of patients (below 18 years) transplanted in the first 6 months of the previous 7 month reporting period</p> <p><b>CPT CODES: 38240, 38241, 38242</b></p> <p><b><u>Denominator Exclusion:</u></b></p> <ul style="list-style-type: none"> <li>• Transplants sourced from umbilical cord blood</li> </ul>
<b>Reporting Frequency</b>	Quarterly
<b>Unit Measure</b>	Percentage
<b>International comparison if available</b>	<ul style="list-style-type: none"> <li>• NHS England. <i>Specialised services quality dashboards metrics metadata (2025–2026)</i>. Published June 30, 2023. Updated May 8, 2026.</li> <li>• NHS England. <i>Specialised services quality dashboards</i>.</li> </ul>
<b>Desired Direction</b>	Higher is better
<b>Data Source</b>	Electronic Medical Record (EMR)

## Jawda HSCT Quality Performance Indicators

Type: Haematopoietic Stem Cell Transplantation

Number: HSCT003

<b>KPI Description (title):</b>	<b>Percentage of adult patients dying within 100 days of autologous transplant</b>
<b>Domain</b>	Effectiveness
<b>Indicator Type</b>	Outcome
<b>Definition</b>	Percentage of adult patients dying within 100 days of <i>autologous</i> transplant
<b>Calculation</b>	<p><b>Numerator:</b> Number of adult patients (18 years and older) in denominator who died within 100 days of <i>autologous</i> transplant</p> <p><b>Denominator:</b> Total number of <i>autologous</i> transplants for adult patients (18 years and older) in the first 365 days of the previous 465 day reporting period</p> <p><b>CPT CODES: 38241</b></p> <p><b>Denominator Exclusion:</b></p> <ul style="list-style-type: none"> <li>• Loss to follow-up (Patients with unknown survival status who may have died outside the UAE)</li> <li>• Patients who received CART post-transplant</li> </ul>
<b>Reporting Frequency</b>	Quarterly
<b>Unit Measure</b>	Percentage of BMT died within 100 days of <i>autologous</i> transplant
<b>International comparison if available</b>	<ul style="list-style-type: none"> <li>• NHS England. <i>Specialised services quality dashboards metrics metadata (2025–2026)</i>. Published June 30, 2023. Updated May 8, 2026.</li> <li>• NHS England. <i>Specialised services quality dashboards</i>.</li> </ul>
<b>Desired Direction</b>	Lower is better
<b>Data Source</b>	Electronic Medical Record (EMR)

**Jawda HSCT Quality Performance Indicators**

---

Type: Haematopoietic Stem Cell Transplantation

Number: HSCT004

<b>KPI Description (title):</b>	<b>Percentage of pediatric patients dying within 100 days of autologous transplant</b>
<b>Domain</b>	<b>Effectiveness</b>
<b>Indicator Type</b>	<b>Outcome</b>
<b>Definition</b>	Percentage of pediatric patients dying within 100 days of <i>autologous</i> transplant
<b>Calculation</b>	<p><b>Numerator:</b> Number of pediatric patients (below 18 years) in denominator who died within 100 days of <i>autologous</i> transplant</p> <p><b>Denominator:</b> Total number of <i>autologous</i> transplants for pediatric patients (below 18 years) in the first 365 days of the previous 465-day reporting period</p> <p><b>CPT CODES: 38241</b></p> <p><b>Denominator Exclusion:</b></p> <ul style="list-style-type: none"> <li>• Loss to follow-up (Patients with unknown survival status who may have died outside the UAE)</li> <li>• Patients who received CART post-transplant</li> </ul>
<b>Reporting Frequency</b>	Quarterly
<b>Unit Measure</b>	Percentage of BMT died within 100 days of <i>autologous</i> transplant
<b>International comparison if available</b>	<ul style="list-style-type: none"> <li>• NHS England. <i>Specialised services quality dashboards metrics metadata (2025–2026)</i>. Published June 30, 2023. Updated May 8, 2026.</li> <li>• NHS England. <i>Specialised services quality dashboards</i>.</li> </ul>
<b>Desired Direction</b>	Lower is better
<b>Data Source</b>	Electronic Medical Record (EMR)

## Jawda HSCT Quality Performance Indicators

Type: Haematopoietic Stem Cell Transplantation

Number: HSCT005

<b>KPI Description (title):</b>	<b>Percentage of adult patients alive at 1 year post autologous transplant</b>
<b>Domain</b>	Effectiveness
<b>Indicator Type</b>	Outcome
<b>Definition</b>	Percentage of adult patients alive at 1 year post <i>autologous</i> transplant
<b>Calculation</b>	<p><b>Numerator:</b> Number of adult patients (18 years and older) in denominator alive 1 year after <i>autologous transplant</i></p> <p><b>Denominator:</b> Total number of <i>autologous transplants</i> for adult patients (18 years and older) <i>in</i> the first 12 months of the previous 24-month reporting period.</p> <p><b>CPT CODES: 38241</b></p> <p><b>Denominator Exclusion:</b></p> <ul style="list-style-type: none"> <li>• Loss to follow-up (Patients with unknown survival status who may have died outside the UAE)</li> <li>• Patients who received CART post-transplant</li> </ul>
<b>Reporting Frequency</b>	Annual
<b>Unit Measure</b>	Percentage of survival at 1 year after <i>autologous transplant</i>
<b>International comparison if available</b>	<ul style="list-style-type: none"> <li>• NHS England. <i>Specialised services quality dashboards metrics metadata (2025–2026)</i>. Published June 30, 2023. Updated May 8, 2026.</li> <li>• NHS England. <i>Specialised services quality dashboards</i>.</li> </ul>
<b>Desired Direction</b>	Higher is better
<b>Data Source</b>	Electronic Medical Record (EMR)

## Jawda HSCT Quality Performance Indicators

Type: Haematopoietic Stem Cell Transplantation

Number: HSCT006

<b>KPI Description (title):</b>	<b>Percentage of pediatric patients alive at 1 year post autologous transplant</b>
<b>Domain</b>	Effectiveness
<b>Indicator Type</b>	Outcome
<b>Definition</b>	Percentage of pediatric patients alive at 1 year post <i>autologous</i> transplant
<b>Calculation</b>	<p><b>Numerator:</b> Number of pediatric patients (below 18 years) in denominator alive 1 year after <i>autologous transplant</i></p> <p><b>Denominator:</b> Total number of <i>autologous transplants</i> for pediatric patients (below 18 years) <i>in</i> the first 12 months of the previous 24-month reporting period.</p> <p><b>CPT CODES: 38241</b></p> <p><b>Denominator Exclusion:</b></p> <ul style="list-style-type: none"> <li>• Loss to follow-up (Patients with unknown survival status who may have died outside the UAE)</li> <li>• Patients who received CART post-transplant</li> </ul>
<b>Reporting Frequency</b>	Annual
<b>Unit Measure</b>	Percentage of survival at 1 year after <i>autologous transplant</i>
<b>International comparison if available</b>	<ul style="list-style-type: none"> <li>• NHS England. <i>Specialised services quality dashboards metrics metadata (2025–2026)</i>. Published June 30, 2023. Updated May 8, 2026.</li> <li>• NHS England. <i>Specialised services quality dashboards</i>.</li> </ul>
<b>Desired Direction</b>	Higher is better
<b>Data Source</b>	Electronic Medical Record (EMR)

**Jawda HSCT Quality Performance Indicators**

---

Type: Haematopoietic Stem Cell Transplantation

Number: HSCT007

<b>KPI Description (title):</b>	<b>Percentage of adult patients dying within 100 days of allogeneic transplant</b>
<b>Domain</b>	Effectiveness
<b>Indicator Type</b>	Outcome
<b>Definition</b>	Percentage of adult patients dying within 100 days of <b>allogeneic</b> transplant
<b>Calculation</b>	<p><b>Numerator:</b> Number of adult patients (18 years and older) in denominator who died within 100 days of <b>allogeneic</b> transplant</p> <p><b>Denominator:</b> Total number of <b>allogeneic</b> transplants for adult patients (18 years and older) in the first 365 days of the previous 465 days reporting period</p> <p><b>CPT CODES: 38240, 38242</b></p> <p><b>Denominator Exclusion:</b></p> <ul style="list-style-type: none"> <li>• Loss to follow-up (Patients with unknown survival status who may have died outside the UAE)</li> <li>• Patients who received CART post-transplant</li> </ul>
<b>Reporting Frequency</b>	Quarterly
<b>Unit Measure</b>	Percentage of BMT died within 100 days of <b>allogeneic</b> transplant
<b>International comparison if available</b>	<ul style="list-style-type: none"> <li>• NHS England. <i>Specialised services quality dashboards metrics metadata (2025–2026)</i>. Published June 30, 2023. Updated May 8, 2026.</li> <li>• NHS England. <i>Specialised services quality dashboards</i>.</li> </ul>
<b>Desired Direction</b>	Lower is better
<b>Data Source</b>	Electronic Medical Record (EMR)

## Jawda HSCT Quality Performance Indicators

Type: Haematopoietic Stem Cell Transplantation

Number: HSCT008

<b>KPI Description (title):</b>	<b>Percentage of pediatric patients dying within 100 days of allogeneic transplant</b>
<b>Domain</b>	<b>Effectiveness</b>
<b>Indicator Type</b>	<b>Outcome</b>
<b>Definition</b>	Percentage of pediatric patients dying within 100 days of <i>allogeneic</i> transplant
<b>Calculation</b>	<p><b>Numerator:</b> Number of pediatric patients (below 18 years) in denominator who died within 100 days of <i>allogeneic</i> transplant</p> <p><b>Denominator:</b> Total number of <i>allogeneic</i> transplants for pediatric patients (below 18 years) in the first 365 days of the previous 465 day reporting period</p> <p><b>CPT CODES: 38240, 38242</b></p> <p><b>Denominator Exclusion:</b></p> <ul style="list-style-type: none"> <li>• Loss to follow-up (Patients with unknown survival status who may have died outside the UAE)</li> <li>• Patients who received CART post-transplant</li> </ul>
<b>Reporting Frequency</b>	Quarterly
<b>Unit Measure</b>	Percentage of BMT died within 100 days of <i>allogeneic</i> transplant
<b>International comparison if available</b>	<ul style="list-style-type: none"> <li>• NHS England. <i>Specialised services quality dashboards metrics metadata (2025-2026)</i>. Published June 30, 2023. Updated May 8, 2026.</li> <li>• NHS England. <i>Specialised services quality dashboards</i>.</li> </ul>
<b>Desired Direction</b>	Lower is better
<b>Data Source</b>	Electronic Medical Record (EMR)

## Jawda HSCT Quality Performance Indicators

Type: Haematopoietic Stem Cell Transplantation

Number: HSCT009

<b>KPI Description (title):</b>	<b>Percentage of adult patients alive at 1 year post allogeneic transplant</b>
<b>Domain</b>	<b>Effectiveness</b>
<b>Indicator Type</b>	<b>Outcome</b>
<b>Definition</b>	Percentage of adult patients alive at 1 year post <i>allogeneic</i> transplant
<b>Calculation</b>	<p><b>Numerator:</b> Number of adult patients (18 years and older) in denominator alive 1 year after <i>allogeneic</i> transplant</p> <p><b>Denominator:</b> Total number of <i>allogeneic</i> transplants for adult patients (18 years and older) in the first 12 months of the previous 24 month reporting period</p> <p><b>CPT CODES: 38240, 38242</b></p> <p><b>Denominator Exclusion:</b></p> <ul style="list-style-type: none"> <li>• Loss to follow-up (Patients with unknown survival status who may have died outside the UAE)</li> <li>• Patients who received CART post-transplant</li> </ul>
<b>Reporting Frequency</b>	Annual
<b>Unit Measure</b>	Overall survival at 1 year
<b>Exclusions:</b>	Percentage of survival at 1 year after <i>allogeneic</i> transplant
<b>International comparison if available</b>	<ul style="list-style-type: none"> <li>• NHS England. <i>Specialised services quality dashboards metrics metadata (2025–2026)</i>. Published June 30, 2023. Updated May 8, 2026.</li> <li>• NHS England. <i>Specialised services quality dashboards</i>.</li> </ul>
<b>Desired Direction</b>	Higher is better
<b>Data Source</b>	Electronic Medical Record (EMR)

## Jawda HSCT Quality Performance Indicators

Type: Haematopoietic Stem Cell Transplantation

Number: HSCT010

<b>KPI Description (title):</b>	<b>Percentage of pediatric patients alive at 1 year post allogeneic transplant</b>
<b>Domain</b>	<b>Effectiveness</b>
<b>Indicator Type</b>	<b>Outcome</b>
<b>Definition</b>	Percentage of pediatric patients alive at 1 year post <i>allogeneic</i> transplant
<b>Calculation</b>	<p><b>Numerator:</b> Number of pediatric patients (below 18 years) in denominator alive 1 year after <i>allogeneic</i> transplant</p> <p><b>Denominator:</b> Total number of <i>allogeneic</i> transplants for pediatric patients (below 18 years) in the first 12 months of the previous 24 month reporting period</p> <p><b>CPT CODES: 38240, 38242</b></p> <p><b>Denominator Exclusion:</b></p> <ul style="list-style-type: none"> <li>• Loss to follow-up (Patients with unknown survival status who may have died outside the UAE)</li> <li>• Patients who received CART post-transplant</li> </ul>
<b>Reporting Frequency</b>	Annual
<b>Unit Measure</b>	Overall survival at 1 year
<b>Exclusions:</b>	Percentage of survival at 1 year after <i>allogenic</i> transplant
<b>International comparison if available</b>	<ul style="list-style-type: none"> <li>• NHS England. <i>Specialised services quality dashboards metrics metadata (2025–2026)</i>. Published June 30, 2023. Updated May 8, 2026.</li> <li>• NHS England. <i>Specialised services quality dashboards</i>.</li> </ul>
<b>Desired Direction</b>	Higher is better
<b>Data Source</b>	Electronic Medical Record (EMR)

## Jawda HSCT Quality Performance Indicators

Type: Haematopoietic Stem Cell Transplantation

Number: HSCT011

<b>KPI Description (title):</b>	<b>Percentage of adult patients with successful platelet engraftment</b>
<b>Domain</b>	<b>Effectiveness</b>
<b>Indicator Type</b>	<b>Outcome</b>
<b>Definition:</b>	Percentage of adult patients (18 and older) where engraftment was successful (successful defined as count $\geq 20,000/\mu\text{L}$ without transfusion support for 7 consecutive days). <ul style="list-style-type: none"> <li>a) By day plus 28 from <b><i>Peripheral Blood Stem Cells sources</i></b></li> <li>b) By day plus 31 from <b><i>Bone Marrow Harvest Cells sources</i></b></li> </ul>
<b>Calculation:</b>	<p><b><u>Numerator:</u></b> Number of adult patients (18 and older) where engraftment was successful (defined as count <math>\geq 20,000/\mu\text{L}</math> without transfusion support for 7 consecutive days)</p> <p><b><u>Report separately:</u></b></p> <ul style="list-style-type: none"> <li>a) By day plus 28 from <b><i>Peripheral Blood Stem Cells sources</i></b></li> <li>b) By day plus 31 from <b><i>Bone Marrow Harvest Cells sources</i></b></li> </ul> <p><b>CPT CODE: 85049</b></p> <p><b><u>Denominator:</u></b> Total number of adult patients (18 and older) transplanted in the first 6 months of the previous 7 month reporting period</p> <p><b>CPT CODES: 38240, 38241, 38242</b></p> <p><b><u>Report separately:</u></b></p> <ul style="list-style-type: none"> <li>a) Transplants sourced from <b><i>Peripheral Blood Stem Cells</i></b></li> <li>b) Transplants sourced from <b><i>Bone Marrow Harvest</i></b></li> </ul> <p><b><u>Denominator Exclusion:</u></b></p> <ul style="list-style-type: none"> <li>• Transplants sourced from umbilical cord blood</li> </ul>
<b>Reporting Frequency:</b>	Quarterly
<b>Unit of Measure:</b>	Percentage
<b>International comparison if available</b>	<ul style="list-style-type: none"> <li>• NHS England. <i>Specialised services quality dashboards metrics metadata (2025–2026)</i>. Published June 30, 2023. Updated May 8, 2026.</li> <li>• NHS England. <i>Specialised services quality dashboards</i>.</li> </ul>
<b>Desired direction:</b>	Higher is better
<b>Data sources and guidance:</b>	Electronic Medical Record (EMR)

## Jawda HSCT Quality Performance Indicators

Type: Haematopoetic Stem Cell Transplantation

Number: HSCT012

<b>KPI Description (title):</b>	<b>Percentage of pediatric patients with successful platelet engraftment</b>
<b>Domain</b>	<b>Effectiveness</b>
<b>Indicator Type</b>	<b>Outcome</b>
<b>Definition:</b>	<p>Percentage of pediatric patients (below 18 years) where engraftment was successful (successful defined as count <math>\geq 20,000/\mu\text{L}</math> without transfusion support for 7 consecutive days).</p> <p>a) By day plus 28 from <b><i>Peripheral Blood Stem Cells sources</i></b>  b) By day plus 31 from <b><i>Bone Marrow Harvest Cells sources</i></b></p>
<b>Calculation:</b>	<p><b><u>Numerator:</u></b> Number of pediatric patients (below 18 years) where engraftment was successful (defined as count <math>\geq 20,000/\mu\text{L}</math> without transfusion support for 7 consecutive days)</p> <p><b>CPT CODE: 85049</b></p> <p><b><i>Report separately:</i></b>  a) By day plus 28 from <b><i>Peripheral Blood Stem Cells sources</i></b>  b) By day plus 31 from <b><i>Bone Marrow Harvest Cells sources</i></b></p> <p><b><u>Denominator:</u></b> Total number of pediatric patients (below 18 years) transplanted in the first 6 months of the previous 7 month reporting period.</p> <p><b>CPT CODES: 38240, 38241, 38242</b></p> <p><b><i>Report separately:</i></b>  a) Transplants sourced from <b><i>Peripheral Blood Stem Cells</i></b>  b) Transplants sourced from <b><i>Bone Marrow Harvest</i></b></p> <p><b><u>Denominator Exclusion:</u></b></p> <ul style="list-style-type: none"> <li>• Transplants sourced from umbilical cord blood</li> </ul>
<b>Reporting Frequency:</b>	Quarterly
<b>Unit of Measure:</b>	Percentage
<b>International comparison if available</b>	<ul style="list-style-type: none"> <li>• NHS England. <i>Specialised services quality dashboards metrics metadata (2025–2026)</i>. Published June 30, 2023. Updated May 8, 2026.</li> <li>• NHS England. <i>Specialised services quality dashboards</i>.</li> </ul>
<b>Desired direction:</b>	Higher is better
<b>Data sources and guidance:</b>	Electronic Medical Record (EMR)

## Jawda HSCT Quality Performance Indicators

Type: Haematopoetic Stem Cell Transplantation

Number: HSCT013

<b>KPI Description (title):</b>	<b>Percentage of Multiple Myeloma Patients Whose Transplant Eligibility Determination Report is Sent to the Referring Hematologist Within 5 Working Days</b>
<b>Domain</b>	Care Coordination
<b>Indicator Type</b>	Process
<b>Definition:</b>	Percentage of Multiple Myeloma patients (all ages) evaluated for hematopoietic stem cell transplantation (HSCT) whose transplant eligibility determination report is sent to the referring hematologist within 5 working days of the MDT decision / final consultant sign-off.
<b>Calculation:</b>	<p><b><u>Numerator:</u></b> Number of Multiple Myeloma patients (all ages) whose transplant eligibility determination report was sent to the referring hematologist within 5 working days of the MDT decision / final consultant sign-off.</p> <p><b><u>Denominator:</u></b> Total number of Multiple Myeloma patients (all ages) referred to hematopoietic stem cell transplantation (HSCT) or advanced cellular therapy during the reporting period.</p> <p><b><u>Denominator Exclusion:</u></b></p> <ul style="list-style-type: none"> <li>• Eligibility determination not completed by end of reporting period</li> <li>• Patient died before transplant eligibility determination</li> <li>• Missing determination date and/or report transmission date</li> <li>• Patient refusing tests required for eligibility determination</li> </ul>
<b>Reporting Frequency:</b>	Quarterly
<b>Unit of Measure:</b>	Percentage
<b>International comparison if available</b>	<p>In alignment with global expectations for timely clinical communication and continuity of care:</p> <ul style="list-style-type: none"> <li>• The NHS Seven Day Services framework treats timely care-plan communication as a core quality standard.</li> <li>• CMS Transitional Care Management (TCM) services require post-encounter communication within 2 business days and follow-up within 7–14 days.</li> </ul>
<b>Desired direction:</b>	Higher is better
<b>Data sources and guidance:</b>	Electronic Medical Record (EMR)

### Summary of Changes V3 2024

KPI #	Changes
HSCT001- HSCT012	<ul style="list-style-type: none"> <li>Revised CPT codes in denominators</li> <li>Removed sample timelines</li> <li>Updated NHS reference link</li> </ul>
HSCT011- HSCT012	<ul style="list-style-type: none"> <li>Rephrased numerator: (defined as count <math>\geq 20,000/\mu\text{L}</math> without transfusion support for 7 consecutive days)</li> </ul>

### Summary of Changes V4 2025

KPI #	Changes
Submission Timeline	Added submission timeline to further standardize reporting of data
HSCT001- HSCT002, HSCT011- HSCT012,	Added <b>Denominator Exclusion:</b> <ul style="list-style-type: none"> <li>Transplants sourced from umbilical cord blood</li> </ul>
HSCT003- HSCT010	Added <b>Denominator Exclusion:</b> <ul style="list-style-type: none"> <li>Loss to follow-up (Patients with unknown survival status who may have died outside the UAE)</li> <li>Patients who received CART post-transplant</li> </ul>
HSCT011- HSCT012,	Added in <b>Definition and Numerator:</b> <ol style="list-style-type: none"> <li>By day plus 28 from <i>Peripheral Blood Stem Cells sources</i></li> <li>By day plus 31 from <i>Bone Marrow Harvest Cells sources</i></li> </ol> Added in <b>Denominator: Report separately:</b> <ol style="list-style-type: none"> <li>Transplants sourced from <i>Peripheral Blood Stem Cells</i></li> <li>Transplants sourced from <i>Bone Marrow Harvest</i></li> </ol>

### Summary of Changes V5 2026

KPI #	Changes
All KPIs	Updated citation format in <b>International comparison if available</b> , and <b>Data sources and guidance</b>
HSCT013	Added new KPI